At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 900 enrolled
Drug / intervention
Acetaminophen 250 mg and Aspirin 250 mg +1 moredrug
Likely dose
Acetaminophen 250 mg and Aspirin 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Parallel-group, Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of a Combination of Acetaminophen and Aspirin vs Placebo in the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating Acetaminophen 250 mg and Aspirin 250 mg and Placebo for Acute Migraine. Completed, enrolled 900 participants across 19 sites.
Detailed Summary
The purpose of the study is to evaluate the efficacy and safety of acetaminophen and aspirin versus placebo in the acute treatment of migraine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionJul 2014
TodayJul 2026
First PostedOct 31, 2013
Enrollment StartOct 1, 2013
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.7 years ago
Interventions
Acetaminophen 250 mg and Aspirin 250 mgdrug
2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
Placebodrug
2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets